Suppr超能文献

DEGRO 乳腺癌放疗实践指南 IV:浸润性乳腺癌乳房切除术后的放疗。

DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer.

机构信息

Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany,

出版信息

Strahlenther Onkol. 2014 Aug;190(8):705-14. doi: 10.1007/s00066-014-0687-0.

Abstract

BACKGROUND AND PURPOSE

Since the last recommendations from the Breast Cancer Expert Panel of the German Society for Radiation Oncology (DEGRO) in 2008, evidence for the effectiveness of postmastectomy radiotherapy (PMRT) has grown. This growth is based on updates of the national S3 and international guidelines, as well as on new data and meta-analyses. New aspects were considered when updating the DEGRO recommendations.

METHODS

The authors performed a comprehensive survey of the literature. Data from recently published (meta-)analyses, randomized clinical trials and international cancer societies' guidelines yielding new aspects compared to 2008 were reviewed and discussed. New aspects were included in the current guidelines. Specific issues relating to particular PMRT constellations, such as the presence of risk factors (lymphovascular invasion, blood vessel invasion, positive lymph node ratio >20 %, resection margins <3 mm, G3 grading, young age/premenopausal status, extracapsular invasion, negative hormone receptor status, invasive lobular cancer, size >2 cm or a combination of ≥ 2 risk factors) and 1-3 positive lymph nodes are emphasized.

RESULTS

The evidence for improved overall survival and local control following PMRT for T4 tumors, positive resection margins, >3 positive lymph nodes and in T3 N0 patients with risk factors such as lymphovascular invasion, G3 grading, close margins, and young age has increased. Recently identified risk factors such as invasive lobular subtype and negative hormone receptor status were included. For patients with 1-3 positive lymph nodes, the recommendation for PMRT has reached the 1a level of evidence.

CONCLUSION

PMRT is mandatory in patients with T4 tumors and/or positive lymph nodes and/or positive resection margins. PMRT should be strongly considered in patients with T3 N0 tumors and risk factors, particularly when two or more risk factors are present.

摘要

背景与目的

自 2008 年德国放射肿瘤学会(DEGRO)乳腺癌专家小组发布最后一次建议以来,乳腺癌术后放疗(PMRT)的有效性证据不断增加。这些增长基于国家 S3 指南和国际指南的更新,以及新数据和荟萃分析。在更新 DEGRO 建议时,考虑了新的方面。

方法

作者对文献进行了全面调查。审查并讨论了最近发表的(荟萃)分析、随机临床试验和国际癌症协会指南的数据,这些数据与 2008 年相比产生了新的方面。新的方面被纳入当前的指南。与特定 PMRT 组合有关的特定问题,例如存在危险因素(脉管侵犯、血管侵犯、阳性淋巴结比例>20%、切除边缘<3mm、G3 分级、年轻/绝经前状态、包膜外侵犯、阴性激素受体状态、浸润性小叶癌、大小>2cm 或≥2 个危险因素)和 1-3 个阳性淋巴结,被强调。

结果

PMRT 改善 T4 肿瘤、阳性切缘、>3 个阳性淋巴结和具有脉管侵犯、G3 分级、切缘接近和年轻等危险因素的 T3 N0 患者的总生存和局部控制的证据增加。最近确定的危险因素,如浸润性小叶癌亚型和阴性激素受体状态被包括在内。对于 1-3 个阳性淋巴结的患者,PMRT 的建议已达到证据 1a 水平。

结论

PMRT 是 T4 肿瘤和/或阳性淋巴结和/或阳性切缘患者的强制性治疗。PMRT 应强烈考虑 T3 N0 肿瘤和危险因素患者,特别是当存在两个或多个危险因素时。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验